Work

Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials

Year: 2016

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdv593

Authors: S.S. Ramalingam, K. O'Byrne, M. Boyer, T. Mok, P.A. Jänne, H. Zhang, J. Liang, I. Taylor, E.I. Sbar, L. Paz-Ares

Institutions: Emory University, Winship Cancer Institute, Princess Alexandra Hospital, Chris O’Brien Lifehouse, Chinese University of Hong Kong, Dana-Farber Cancer Institute, Pfizer (United States), Spanish National Cancer Research Centre, Hospital Universitario 12 De Octubre

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: Pfizer

OpenAlex ID: W2273212719

FWCI: 9.826

Cites: 15

Cited by: 57

Related to: 10